These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17073839)

  • 21. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccination.
    Menon VJ; Corscadden KJ; Fuery A; Thornton RB; Kirkham LA; Richmond PC; Wiertsema SP
    Vaccine; 2012 Apr; 30(20):3136-44. PubMed ID: 22326775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.
    Navarro D; Escribano A; Cebrián L; Gimeno C; García-Maset L; García-de-Lomas J;
    Clin Vaccine Immunol; 2006 Jun; 13(6):665-70. PubMed ID: 16760325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus.
    Dagan R; Givon-Lavi N; Fraser D; Lipsitch M; Siber GR; Kohberger R
    J Infect Dis; 2005 Aug; 192(3):367-76. PubMed ID: 15995949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
    Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
    Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.
    Väkeväinen M; Soininen A; Lucero M; Nohynek H; Auranen K; Mäkelä PH; Williams G; Käyhty H;
    J Pediatr; 2010 Nov; 157(5):778-83.e1. PubMed ID: 20547399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.
    Salt P; Banner C; Oh S; Yu LM; Lewis S; Pan D; Griffiths D; Ferry B; Pollard A
    Clin Vaccine Immunol; 2007 May; 14(5):593-9. PubMed ID: 17344347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
    Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
    Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial.
    Lucero MG; Puumalainen T; Ugpo JM; Williams G; Käyhty H; Nohynek H
    J Infect Dis; 2004 Jun; 189(11):2077-84. PubMed ID: 15143476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.
    Givon-Lavi N; Greenberg D; Dagan R
    Pediatr Infect Dis J; 2010 Aug; 29(8):756-62. PubMed ID: 20661103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial.
    Nurkka A; Lahdenkari M; Palmu A; Käyhty H;
    Vaccine; 2004 Dec; 23(3):298-304. PubMed ID: 15530671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.